Withdrawing low risk women from cervical screening programmes: Mathematical modelling study

British Medical Journal

Volumn 318, Issue 7180, 1999, Pages 356-361

  Sherlaw Johnson, C ^a   Gallivan, S ^a   Jenkins, D ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CANCER SCREENING; COLPOSCOPY; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; MATHEMATICAL MODEL; MEDICAL AUDIT; NORMAL HUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; PRECANCER; PRIORITY JOURNAL; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GREAT BRITAIN; HEALTH POLICY; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; REFUSAL TO TREAT; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 0033528210     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 1 Duncan ID, ed. Guidelines for clinical practice and programme management: national coordinating network of the NHS cervical screening programme. Oxford: Oxford Regional Health Authority, 1992.
2. 2 Van Wijngaarden WJ, Duncan ID. Rationale for stopping screening in women over 50. BMJ 1993;306:967-71.
3. 3 Office for National Statistics. Estimates of newly diagnosed cases of cancer: England and Wales 1993-1997. London: DoH, 1998. (Monitor MB1 98/2.)
4. 4 Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
5. 5 Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
6. 6 Jenkins D, Sherlaw-Johnson C, Gallivan S. Assessing the role of HPV testing in cervical cancer screening. Papillomavirus Rep 1998;9:89-101.
7. 7 Schiffman MH, Sherman ME. HPV testing to improve cervical cancer screening. In: Srivastava S, Lippman SM, Hong WK, Mulshine JL. eds. Early detection of cancer: molecular markers. Armonk, New York: Futura Publishing, 1994:265-77.
8. 8 Sherlaw-Johnson C, Gallivan S, Jenkins D, Jones MH. Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. J Clin Pathol 1994;47:430-5.
9. 9 Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papillomavirus testing be used to improve cervical cancer screening? Int J Cancer 1996;65:768-73.
10. 10 Melkert PW, Hopman E, van den Brule AJC, Risse EJK, van Diest PJ, Bleker OP, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993;53:919-23.
11. 11 Department of Health. Cervical screening programme, England: 1995-96. London: DoH, 1996. (Statistical Bulletin 1996/26.)
12. 12 Orbell S, Crombie I, Robertson A, Johnston G, Kenicer M. Assessing the effectiveness of a screening campaign: who is missed by 80% cervical screening coverage. J R Soc Med 1995;88:389-94.
13. 13 Austoker J. Screening for cervical cancer. BMJ 1994;309:241-8.
14. 14 Mandelblatt J, Schechter C, Fahs M, Muller C. Clinical implications of screening for cervical cancer under Medicare. The natural history of cervical cancer in the elderly: what do we know? What do we need to know? Am J Obstet Gynecol 1991;164:644-51.
15. 15 Parkin DM, Leach K, Cobb P, Clayden AD. Cervical cytology screening in two Yorkshire areas: results of testing. Public Health 1982;96:3-14.
16. 16 Rozendaal L, Walboomers JMM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJM, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9
17. 17 Mansell ME, Ho L, Terry G, Singer A, Cuzick J. Semi-quantitative human papillomavirus DNA detection in the management of women with minor cytological abnormality. Br J Obstet Gynaecol 1994;101:807-9.
18. 18 Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytological diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995; 172:946-54.
19. 19 Van Wijngaarden WJ, Duncan ID. Upper age limit for cervical screening. BMJ 1993;306:1409-10.
20. 20 Cruickshank ME, Angus V, Kelly M, McPhee S, Kitchener HC. The case for stopping screening at age 50. Br J Obstet Gynaecol 1997;104:586-9.
21. 21 Sasieni PD, Cuzick J, Lynch-Farmery E. National Co-ordinating Network for Cervical Screening Working Group: estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996;73:1001-5. (Accepted 9 November 1998)